Jasper Therapeutics’ (JSPR) “Market Outperform” Rating Reiterated at JMP Securities

by · The Cerbat Gem

JMP Securities reissued their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a report published on Friday, Benzinga reports. JMP Securities currently has a $70.00 target price on the stock.

Several other brokerages also recently issued reports on JSPR. Evercore ISI reissued an outperform rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. BTIG Research began coverage on shares of Jasper Therapeutics in a research note on Monday, July 8th. They issued a buy rating and a $90.00 price objective for the company. Cantor Fitzgerald reissued an overweight rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Stifel Nicolaus assumed coverage on shares of Jasper Therapeutics in a research note on Thursday, June 27th. They set a buy rating and a $86.00 price target for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $65.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, August 13th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of Buy and an average target price of $73.00.

Check Out Our Latest Stock Report on Jasper Therapeutics

Jasper Therapeutics Trading Down 0.1 %

Shares of NASDAQ:JSPR opened at $18.83 on Friday. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The company has a 50-day moving average price of $19.66 and a 200 day moving average price of $22.45. The company has a market cap of $283.66 million, a price-to-earnings ratio of -3.34 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.12. As a group, equities analysts forecast that Jasper Therapeutics will post -4.16 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

Several institutional investors have recently bought and sold shares of JSPR. Opaleye Management Inc. purchased a new position in Jasper Therapeutics in the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. grew its holdings in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after purchasing an additional 500,000 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in Jasper Therapeutics in the first quarter worth $599,000. Russell Investments Group Ltd. purchased a new position in Jasper Therapeutics in the first quarter worth $2,343,000. Finally, StemPoint Capital LP purchased a new position in Jasper Therapeutics in the first quarter worth $3,794,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

See Also